260 Stock Overview
A clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Centessa Pharmaceuticals plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$8.05 |
| 52 Week High | US$8.45 |
| 52 Week Low | US$8.05 |
| Beta | 1.41 |
| 11 Month Change | 0% |
| 3 Month Change | -2.42% |
| 1 Year Change | n/a |
| 33 Year Change | -55.52% |
| 5 Year Change | n/a |
| Change since IPO | -54.75% |
Recent News & Updates
Recent updates
Shareholder Returns
| 260 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | 0.8% | 0.8% |
| 1Y | n/a | -18.3% | 8.6% |
Return vs Industry: Insufficient data to determine how 260 performed against the German Biotechs industry.
Return vs Market: Insufficient data to determine how 260 performed against the German Market.
Price Volatility
| 260 volatility | |
|---|---|
| 260 Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 6.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 260 has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine 260's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2020 | 77 | Saurabh Saha | www.centessa.com |
Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders. The company also develops LB101, a PD-L1xCD47 LockBody, a bi-specific monoclonal antibody for solid tumors, which is designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; and OX2R Agonists compounds are currently in development for the treatment of narcolepsy.
Centessa Pharmaceuticals plc Fundamentals Summary
| 260 fundamental statistics | |
|---|---|
| Market cap | €1.25b |
| Earnings (TTM) | -€141.42m |
| Revenue (TTM) | €6.16m |
198.8x
P/S Ratio-8.7x
P/E RatioIs 260 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 260 income statement (TTM) | |
|---|---|
| Revenue | US$6.85m |
| Cost of Revenue | US$0 |
| Gross Profit | US$6.85m |
| Other Expenses | US$164.20m |
| Earnings | -US$157.35m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.39 |
| Gross Margin | 100.00% |
| Net Profit Margin | -2,296.03% |
| Debt/Equity Ratio | 26.7% |
How did 260 perform over the long term?
See historical performance and comparison